Pharmaceutical Registration in El Salvador: the DNM to SRS Transition, RTCA and Import Routes

El Salvador is a small, densely populated market that punches above its size for one reason: it took medicines pricing and regulation seriously earlier than most of its neighbours, and built an institution to do it.

That institution has just changed. If you are working from guidance written before late 2024, you are reading about a body that no longer exists in that form.

For an exporter the market is worth understanding on its own terms, but the stronger argument is regional. El Salvador is part of the Central American harmonised framework, so the dossier you build here is the dossier you file in five other countries.

Around six million people in the smallest country in continental Central America, with a correspondingly concentrated healthcare system centred on San Salvador.

There is domestic manufacturing capability — El Salvador has a longer pharmaceutical manufacturing history than several neighbours — but it is oriented towards established generics in common dosage forms. Anything specialised is imported: oncology, biologics, most injectables beyond basics, and essentially all advanced therapies.

That split matters commercially. Competing on plain oral generics means competing with local producers who have lower landed costs and existing tender relationships. The import-dependent categories are where an exporter has a structural position rather than a price argument.

El Salvador is also notable regionally for having implemented medicines price regulation, which shapes what margins are available and should be understood before pricing a market entry.

Oncology. Almost entirely imported. Concentrated in a small number of referral centres, largely funded through the public system and the social security institute. Small absolute volumes, high value per unit, and demand that does not disappear in a downturn.

Biosimilars. A genuine opportunity in a budget-constrained system, and the regional direction of travel favours them. Expect the regulator to want proper comparability evidence rather than treating a biosimilar as an ordinary generic — the dossier expectations are materially different and exporters regularly underestimate this.

Nutraceuticals and food supplements. Worth separating clearly in your planning. The Superintendencia's remit explicitly covers nutritional supplements alongside medicines, but supplements generally follow a lighter registration route than pharmaceuticals. Exporters routinely apply medicine-grade assumptions to a supplement filing and over-engineer it, spending months and money on a pathway that was never required. Establish which category your product falls into before you build anything.

Biotech. Limited local capability, so this is an import market. Cold chain and handling requirements are the binding constraint rather than regulatory appetite.

Shortage risk in El Salvador is structural rather than episodic, and the causes repeat.

Single-source dependence. A small market often supports only one registered supplier for a given specialised product. When that supplier has a manufacturing interruption, a regulatory hold or simply decides the market is not worth the renewal, there is no second source already registered — and standing one up takes months, not days.

Tender cycle gaps. Where public procurement runs on annual or semi-annual cycles, a failed or delayed tender creates a supply hole that nothing fills until the next round. This is one of the more common triggers for urgent unregistered-import requests across Central America.

Price regulation interacting with cost. Where a regulated price ceases to cover a supplier's landed cost — because of API price movement, freight, or currency — the rational response is to stop supplying. Shortages of this kind are economic, not logistical, and they tend to hit older, cheap, essential products rather than new expensive ones.

Categories that recur. Oncology agents, specialised injectables and anaesthetics, paediatric formulations, and older essential medicines with thin margins. The pattern is consistent regionally: the products that go short are usually the ones nobody makes much money on.

For a supplier who can respond quickly with proper documentation, these gaps are the most common way a first relationship with an institution begins.

This is the part most published guidance gets wrong.

Medicines in El Salvador were regulated by the Dirección Nacional de Medicamentos (DNM), established under the Medicines Law and long regarded as one of the more capable regulators in Central America.

The DNM has been transformed into the Superintendencia de Regulación Sanitaria (SRS), effective from August 2024. The SRS carries a broader remit than the DNM did — medicines, nutritional supplements, medical devices and equipment, sanitary technologies, cosmetics, hygiene products for human and veterinary use, chemical products, food, beverages, alcohol, tobacco and nicotine-delivery devices.

El Salvador participates as an observer agency at the Pan American Health Organization's Regional Reference Regulatory Authorities meetings, and the SRS has signed cooperation arrangements with neighbouring regulators including Honduras's ARSA — a practical sign that Central American regulatory convergence is being actively worked rather than merely declared.

What this means for you: confirm current procedure, the responsible unit and the filing route directly with the SRS. Advice referring to the DNM may still be broadly right on substance and wrong on process.

Short answer: registration is the rule, and defined exceptional routes exist.

Placing a medicine on the Salvadoran market normally requires sanitary registration. You cannot supply commercially on the basis of an import permit alone.

Alongside that, authorisations exist for genuine clinical need the registered market cannot meet — no registered equivalent, shortage, public health need, orphan products, named patient supply and clinical trial material. These are consignment-specific and justification-based, not a parallel commercial channel.

So if your question is "can I sell here without registering", the answer is no. If it is "can I supply an urgent institutional need while a registration is in progress", the answer is often yes, subject to authorisation.

RTCA format. El Salvador applies the Central American Technical Regulation for pharmaceutical registration, harmonised across Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica and Panama and approved through COMIECO.

The RTCA requirement set draws on the same scientific content as the ICH Common Technical Document, so a CTD-format dossier is the right raw material — but it is reorganised and supplemented to the RTCA structure rather than filed as-is. If you hold an EU or US CTD dossier, you are not starting from zero, but you are not finished either.

ACTD format, used across ASEAN, is not relevant here and should not be offered.

The practical point: build one RTCA-compliant dossier for the region, not six national ones. Requirements are harmonised even though registrations are not.

WHO-GMP is the practical baseline across Central America, and El Salvador is no exception. A valid WHO-format GMP certificate from a recognised authority, supported by a CoPP, is the standard expectation for an imported product.

Above that baseline, stronger credentials carry real weight rather than merely looking good:

• EU-GMP — treated as a strong signal, particularly for injectables, biologics and biosimilars.
• US FDA inspection history — carries weight, and is relevant to reliance arguments.
• PIC/S membership of the certifying authority — increasingly recognised across the region.

Within the Central American framework, a certificate issued by a stringent regulatory authority may support safety and efficacy in defined cases even where that authority is not in the holder's country of origin. That makes the identity of your certifying authority a commercial variable, not just a compliance box.

For sterile products, biologics and oncology in particular, a site with only a basic national GMP certificate and no stringent-authority history will face a harder path — and will be at a disadvantage in tender technical evaluation even where it is formally eligible.

A locally established entity must hold the registration and answer to the regulator.

The usual trade-off applies — distributor-held is fast and cheap but ties your market access to that relationship; your own entity or an independent regulatory representative costs more and keeps the registration portable.

Because El Salvador is one of six RTCA markets you are likely to enter, decide early whether one partner holds your registrations across the bloc or whether they are held separately. A single regional partner is simpler and hands them considerable leverage over your entire Central American position. That may still be the right answer — but it should be a decision, not the result of signing whatever the first capable partner proposed.

Expect the RTCA set: CoPP in WHO format legalised for use in El Salvador, GMP certificate, manufacturing licence, finished product specification and validated method of analysis with validation reports, batch Certificate of Analysis, stability data for the applicable tropical zone, bioequivalence data where required, Spanish labelling and insert to RTCA standards, and a legalised power of attorney.

Confirm the current requirement list with the SRS rather than working from DNM-era documentation.

RTCA harmonisation is the main lever. The marginal cost of each additional Central American filing sits far below the first, which argues for treating the region as one programme rather than six opportunities.

Reliance on established authorities. The Pan American Health Organization designates eight Regional Reference Regulatory Authorities — ANMAT, ANVISA, Health Canada, ISP, INVIMA, CECMED, US FDA and COFEPRIS. An approval from one of these, or from a stringent authority such as the EMA, can carry part of the evidence burden. COFEPRIS is often the most practically relevant given Mexican pharmaceutical presence across the region.

Regional cooperation. The SRS has cooperation arrangements with neighbouring regulators including ARSA in Honduras. Where recognition or shared assessment applies, the filing order across the bloc matters — worth asking about before filing six applications in parallel.

Reliance is at the receiving authority's discretion and varies by product. Confirm before building a timeline on it.

Deficiency cycles drive elapsed time far more than the published review period does, and an institution in transition will generally produce more of them while procedures settle.

Get confirmations in writing during this period. Informal guidance has a short shelf life when responsibilities are moving between bodies.

Registrations run for a fixed term and require renewal. If you hold registrations across the RTCA bloc, track all six in one place — the lapse always happens in the market nobody was watching.

El Salvador is a party to the Hague Apostille Convention, as is India, so public documents can generally be apostilled rather than put through full consular legalisation. Confirm before arranging consular appointments.

The recurring friction points are regional constants: CoPP validity expiring before the filing completes, commercial documents needing notarisation to qualify for apostille, certified Spanish translation to local formal standards, and exact name consistency across every document.

Filing across the bloc, sequence certificate issuance so one CoPP validity window covers as many applications as possible.

Exceptional import routes cover situations the registered market cannot meet: no registered equivalent, shortage or supply interruption, public health need or declared emergency, orphan and rare disease products, and clinical trial material under its own authorisation.

Conditions are the regional standard. Authorisation attaches to a consignment and a stated justification. The importing institution or licensed importer applies, not the foreign manufacturer — your role is documentation that is complete and fast. And it is not a substitute for registration where supply is to be continuous.

Given the shortage patterns described above, this route is used more often in El Salvador than the formal framework might suggest. Being genuinely quick with a complete document pack when a hospital has a gap is a commercial position that is difficult to compete with on price alone.

Confirm current conditions with the SRS.

An unregistered medicine may be imported for an individually identified patient, on a treating physician's responsibility, where no suitable registered alternative exists.

Typically required: prescription naming the patient, clinical justification, authority authorisation before the goods move, quantity limited to the treatment course, batch CoA and provenance documentation.

Compassionate use and expanded access for products still in clinical development sit under a separate framework.

El Salvador's small size works in your favour operationally — the specialist centres are concentrated, distances are short, and a consignment reaching San Salvador is effectively at its destination. That is not true in Guatemala or Honduras, where the final leg can be the hard part.

Further reading: our global guide to named patient import programmes, our named patient supply service, and our cold chain logistics page.

Public demand runs through the Ministry of Health and through the social security institute, ISSS (Instituto Salvadoreño del Seguro Social), which covers formally employed workers and their families and is a substantial purchaser in its own right. They procure separately — treat them as two customers.

A valid registration is generally required to bid, so registration is infrastructure built ahead of tenders rather than a response to them.

Procurement is price-competitive and the price-regulation environment reinforces that. If your commercial case depends on a premium, test the assumption before investing in entry.

The PAHO Strategic Fund is available as a parallel route — pooled procurement for member states that have signed an agreement with the Organization, with eligibility resting on WHO Prequalification status at tender opening or approval by regulatory authorities of regional reference, rather than separate national registration in each purchasing country. For WHO Prequalified products this deserves examination before committing to a national registration project. Confirm current criteria with PAHO.

Our government and institutional tender supply page sets out what the technical file must contain.

The problems importers actually run into here, as distinct from the problems the regulations describe:

• Working from DNM-era guidance. The most current and most avoidable error — process references that no longer match the SRS.
• Price regulation squeezing viability. A regulated ceiling that made sense at one API price may not cover landed cost after currency and freight movement. Model this before entry, not after.
• Payment terms and public-sector cycles. Institutional payment timelines can be long. Factor the working capital cost into your pricing rather than discovering it in year two.
• Registration cost against market size. Six million people. A full registration project has to be justified either by the volume here or — more usually — by the fact that the same dossier serves five other countries.
• Single-source exposure cutting both ways. Being the only registered supplier is commercially strong and operationally risky. Any interruption on your side becomes a national shortage, with the reputational consequences that follow.
• Expired or mismatched certificates — the most common technical cause of avoidable delay anywhere in the region.
• Tropical stability data. Data generated for temperate markets will not support labelling here.

The documentation burden scales with the route. Matching the level to the route saves both money and months.

Check the SRS position before anything else. The institution changed in 2024 and a great deal of circulating advice has not caught up — including confident advice from people who registered here successfully under the DNM.

Decide your product category early, particularly for anything that could be a supplement rather than a medicine. The pathways are different and the cheaper one is easy to miss.

Think regionally about the dossier and locally about the price. One RTCA dossier serves six countries; the pricing and margin analysis has to be done market by market, and El Salvador's price regulation makes that especially true here.

Be honest about whether you can compete on plain generics against local manufacturers. If not, aim at the import-dependent categories where you have a structural position rather than a price argument.

Not legal advice. Confirm current requirements with the SRS and take local advice before committing funds.